Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tiplimotide
- Development stage
- Phase 2
- Lead developer
- Neurocrine Biosciences
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous
01
Overview
Tiplimotide is a synthetic peptide analog of an immunodominant epitope of myelin basic protein (MBP), specifically designed as an altered peptide ligand for the potential treatment of multiple sclerosis (MS). It was developed to modulate immune responses by inducing a T-helper 2-like immune response in MS patients, thereby reducing the autoimmune attack on myelin. Tiplimotide was investigated as an intravenous therapy and reached phase II clinical trials for relapsing forms of MS. However, its development has been discontinued[1][2][4]. The drug is classified as a protein-based biologic and falls under the category of peptides[1][3].
- Other names
- tiplimotideNBI-5788NBI5788NBI 5788UNII-6VN101530YUNII6VN101530YUNII 6VN101530Y178823-49-9
02
Targets
Insulin B chain epitope-specific T-cell receptorMajor histocompatibility complex class II presenting myelin basic protein 83-99Type II collagen-specific T-cell receptor
Beyond the preview
Go deeper on tiplimotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tiplimotide.